DR. LEONG SZE WEI
Department of Chemistry
Faculty of Science
leongszeweium.edu.my| View CV | |
| View 1-Page CV | |
| Publons | |
| Scopus Link | |
| Biography | |
|
Sze Wei Leong received his PhD in medicinal chemistry from Univeristi Putra Malaysia in 2014, for which he was awarded the National Science Fellowship (NSF) Scholarship from the Malaysian Ministry of Science, Technology and Innovation (MoSTI). Upon completion of his PhD, he was appointed as an assistant researcher in natural product chemistry at the Laboratory of Natural Products, Institute of Bioscience, Universiti Putra Malaysia. In 2017, he was appointed as a post-doctoral fellow in cancer pharmacology at the Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia. His doctoral and post-doctoral experiences have equipped him with knowledge and techniques in medicinal chemistry, natural product chemistry, and cancer pharmacology. His research is now focusing on small molecule-based drug discovery, particularly in the search of synthetic multi-functional anti-cancer drugs. |
|
Publication
Finance
| Project Title | Progress | Status |
|---|---|---|
| Structural Derivatization And In-vitro Anti-cancer Evaluations Of Phenylpyrazole-styryl Hybrids As Multi-target Inhibitor Against Egfr, Vegfr-2 And Vegfr-3 To Combat Metastatic Cancer. |
|
new |
| Design, Synthesis And Anti-cancer Evaluation Of Phenylpyrazole-styryl Hybrids As Multi Target Agents Against Egfr And Vegfrs |
|
end |
| Structural Optimization of AP21 as EGFR-Targeting Anti-Cancer Agents |
|
end |
| This information is generated from Research Grant Management System | ||
Novel 2-Anilinoquinazoline derivatives as apoptosis-inducing agents in drug-resistant NSCLC cells: Integrating biological and computational evaluation
Indole Schiff Base Complex: Synthesis and Optical Binding Investigation with Biogenic Amines
Preliminary insight on diarylpentanoids as potential antimalarials: In silico, in vitro <i>p</i>LDH and in vivo zebrafish toxicity assessment
Parkin deficiency promotes liver cancer metastasis by TMEFF1 transcription activation via TGF-β/Smad2/3 pathway
